{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=10", "query": { "condition": "Multiple Cancers", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 4774, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:47:36.010Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00324155", "title": "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 681, "start_date": "2006-08", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-11-03", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 32, "location_summary": "Anaheim, California • La Verne, California • Los Angeles, California + 28 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324155" }, { "nct_id": "NCT02514525", "title": "Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Barrett Esophagus" ], "interventions": [ { "name": "CryoBalloon Ablation System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Pentax Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-03", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 11, "location_summary": "Orange, California • Sarasota, Florida • Chicago, Illinois + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02514525" }, { "nct_id": "NCT04184050", "title": "Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma", "Multiple Myeloma of Bone", "Multiple Myeloma With Failed Remission" ], "interventions": [ { "name": "MK-4002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-04-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04184050" }, { "nct_id": "NCT00375791", "title": "Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "perifosine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2005-12", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 7, "location_summary": "Berkeley, California • Duarte, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375791" }, { "nct_id": "NCT06115135", "title": "A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 39, "start_date": "2024-06-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 2, "location_summary": "West Hollywood, California • Omaha, Nebraska", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06115135" }, { "nct_id": "NCT00900055", "title": "Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Fanconi Anemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "microarray analysis", "type": "GENETIC" }, { "name": "polyacrylamide gel electrophoresis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "chromatography", "type": "OTHER" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "55 Years", "sex": "ALL", "summary": "1 Year to 55 Years" }, "enrollment_count": 213, "start_date": "1975-06", "completion_date": "2016-08-23", "has_results": false, "last_update_posted_date": "2022-07-05", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900055" }, { "nct_id": "NCT07390643", "title": "The DISCOVER Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Cancer Diagnosis" ], "interventions": [ { "name": "GRAIL Galleri MCED test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 100, "start_date": "2026-07", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07390643" }, { "nct_id": "NCT00386516", "title": "Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer of the Bile Duct", "Gallbladder Cancer" ], "interventions": [ { "name": "GM-CT-01", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galectin Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2006-09", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386516" }, { "nct_id": "NCT02639065", "title": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shadia Jalal, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2016-04-27", "completion_date": "2021-06-09", "has_results": true, "last_update_posted_date": "2023-09-25", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • Iowa City, Iowa • Ann Arbor, Michigan", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639065" }, { "nct_id": "NCT00012311", "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "CMF regimen", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "18 Years to 59 Years · Female only" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-10-23T14:47:36.010Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012311" } ] }